PT - JOURNAL ARTICLE AU - Ramatillah, Diana Laila AU - Isnaini, Suri TI - TREATMENT PROFILES AND CLINICAL OUTCOMES OF COVID-19 PATIENTS AT PRIVATE HOSPITAL IN JAKARTA AID - 10.1101/2020.10.14.20212449 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.14.20212449 4099 - http://medrxiv.org/content/early/2020/10/16/2020.10.14.20212449.short 4100 - http://medrxiv.org/content/early/2020/10/16/2020.10.14.20212449.full AB - Background Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a virus that causes COVID-19, which has become a worldwide pandemic. However, until now, there is no vaccine or specific drug to prevent or treat COVID-19.Objectives To find out the effective treatment as an antiviral agent for COVID-19, to determine the correlation between sociodemography with clinical outcomes and duration of treatment, and to determine the relationship between comorbidities with clinical outcomes and duration of treatment for COVID-19 patients.Methods A prospective cohort study was conducted in this study. This study included only confirmed COVID-19 patients who were admitted to the hospital during April-May 2020. Convenience sampling was used to select 103 patients, but only 72 patients were suitable for inclusion.Results The survival analysis for COVID-19 patients using the Kaplan Meier method showed that patients receiving Oseltamivir + Hydroxychloroquine had an average survival rate of about 83% after undergoing treatment for about ten days. Gender (p = 0.450) and age (p = 0.226) did not have a significant correlation with the duration of treatment for COVID-19 patients. Gender (p = 0.174) and age (p = 0.065) also did not have a significant correlation with clinical outcome of COVID-19 patients. Comorbidities showed a significant correlation with duration of treatment (p = 0.002) and clinical outcome (p = 0.014) of COVID-19 patients.Conclusion The most effective antiviral agent in this study based on treatment duration was the combination of Oseltamivir + Hydroxychloroquine. The higher the patient’s average treatment duration, the lower the average survival rate for COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo FundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Nomor : 0303-20.283/DPKE-KEP/FINAL-EA/UEU/IX/2020 KETERANGAN LOLOS KAJI ETIK ETHICAL APPROVAL Komisi Etik Penelitian Universitas Esa Unggul dalam upaya melindungi hak asasi dan kesejahteraan subyek penelitian kesehatan, telah mengkaji dengan teliti protokol berjudul: PROFIL PENGOBATAN DAN CLINICAL OUTCOME PASIEN COVID-19 DI RUMAH SAKIT PERTAMINA JAYA JAKARTA Peneliti Utama Pembimbing Nama Institusi Suri Isnaini ' Dr. apt. Diana Laila Ramatillah, M.Farm. : Universitas 17 Agustus 1945 Jakarta dan telah menyetujui protokol tersebut di atas. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data are available in manuscript